Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The...

Full description

Bibliographic Details
Main Authors:	Ayşe Demirci, Cemil Bilir, Burcu Gülbağcı, İlhan Hacıbekiroğlu, İbrahim V. Bayoğlu, İrem Bilgetekin, Sinan Koca, Havva Y. Çınkır, Nadiye Akdeniz, Deniz Gül, Ceyhun Varım, Umut Demirci, Berna Öksüzoğlu
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-07-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-93659-x

Similar Items

Influence of treatment with abiraterone and enzalutamide on development of sarcopenia in patients with metastatic castration resistant prostate cancer
by: S. Fischer, et al.
Published: (2020-07-01)

Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2017-10-01)

Observational study on time on treatment with abiraterone and enzalutamide.
by: Giuseppe Fallara, et al.
Published: (2020-01-01)

Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-07-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
by: Mike Fang, et al.
Published: (2017-01-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide
by: Juan José Serrano Domingo, et al.
Published: (2021-09-01)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
by: Yi-Ting Lin, et al.
Published: (2021-05-01)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models is Mediated by AR Transcriptional Reactivation
by: Iris Simon, et al.
Published: (2021-03-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data
by: P. V. Mazin, et al.
Published: (2018-01-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
by: Stephanie I Kim, et al.
Published: (2021-01-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: ZhenHeng Wei, et al.
Published: (2021-08-01)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
by: Rachel Raju, et al.
Published: (2021-06-01)

Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide
by: E.B. Cone, et al.
Published: (2020-07-01)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01)

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
by: Maurizio Valeriani, et al.
Published: (2019-11-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies
by: Ece Esin, et al.
Published: (2019-12-01)

Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Xin Wang, et al.
Published: (2020-11-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
by: Celeste Nicola, et al.
Published: (2021-07-01)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
by: Takashi Kawahara, et al.
Published: (2020-09-01)

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Luigi Rossi, et al.
Published: (2021-03-01)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
by: Yasushi Nakai, et al.
Published: (2018-05-01)

Comparison of outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide: A population-based study
by: D.T.S. Woon, et al.
Published: (2020-07-01)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015-06-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel EA
Published: (2014-01-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: S. Feyerabend, et al.
Published: (2020-07-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-08-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-01-01)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
by: Ramadan WH, et al.
Published: (2015-04-01)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
by: Tucci M, et al.
Published: (2018-10-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
by: Benjamin A. Gartrell, et al.
Published: (2015-08-01)

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
by: Lu Xu, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_8u8g6gt6sbvelr0nobr319pt6t